Literature DB >> 29249634

The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure.

Masanori Hirose1, Hiroyuki Takano2, Hiroshi Hasegawa1, Hiroyuki Tadokoro1, Naoko Hashimoto3, Genzo Takemura4, Yoshio Kobayashi1.   

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known. Our aim was to determine the effects of DPP-4 on cardiac fibrosis in murine TAC model. Wild-type mice and DPP-4 knockout mice were subjected to TAC. Wild-type mice were then treated with vehicle or DPP-4 inhibitor. DPP-4 activities in serum and heart tissue were significantly increased at 2 weeks after TAC, but they were significantly decreased by DPP-4 inhibitor treatment. The inhibition of DPP-4 did not affect left ventricular hypertrophy, but improved cardiac function and decreased myocardial and perivascular fibrosis after TAC. The inhibition of DPP-4 decreased the collagen type III/I ratio in myocardium. These results suggest that DPP-4 inhibition ameliorates the progression of heart failure after TAC by changing the quality and quantity of cardiac fibrosis.
Copyright © 2017 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Collagen; DPP-4; Heart failure; cardiac fibrosis

Mesh:

Substances:

Year:  2017        PMID: 29249634     DOI: 10.1016/j.jphs.2017.11.006

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

1.  GDF11 Decreases Pressure Overload-Induced Hypertrophy, but Can Cause Severe Cachexia and Premature Death.

Authors:  Shavonn C Harper; Jaslyn Johnson; Giulia Borghetti; Huaqing Zhao; Tao Wang; Markus Wallner; Hajime Kubo; Eric A Feldsott; Yijun Yang; Yunichel Joo; Xinji Gou; Abdel Karim Sabri; Priyanka Gupta; Maria Myzithras; Ashraf Khalil; Michael Franti; Steven R Houser
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

Review 2.  Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.

Authors:  Bárbara Torrecillas-Baena; María Ángeles Gálvez-Moreno; José Manuel Quesada-Gómez; Gabriel Dorado; Antonio Casado-Díaz
Journal:  Stem Cell Rev Rep       Date:  2021-10-22       Impact factor: 5.739

Review 3.  New antidiabetic therapy and HFpEF: light at the end of tunnel?

Authors:  Marijana Tadic; Carla Sala; Sahrai Saeed; Guido Grassi; Giuseppe Mancia; Wolfang Rottbauer; Cesare Cuspidi
Journal:  Heart Fail Rev       Date:  2021-04-11       Impact factor: 4.654

4.  Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.

Authors:  Chengcong Chen; Ying Huang; Yongmei Zeng; Xiyan Lu; Guoqing Dong
Journal:  BMC Cardiovasc Disord       Date:  2019-12-23       Impact factor: 2.298

Review 5.  The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy.

Authors:  Keshav Gopal; Jadin J Chahade; Ryekjang Kim; John R Ussher
Journal:  Front Physiol       Date:  2020-12-07       Impact factor: 4.566

Review 6.  Renoprotective Effects of DPP-4 Inhibitors.

Authors:  Daiji Kawanami; Yuichi Takashi; Hiroyuki Takahashi; Ryoko Motonaga; Makito Tanabe
Journal:  Antioxidants (Basel)       Date:  2021-02-05

Review 7.  DPP4 as a Potential Candidate in Cardiovascular Disease.

Authors:  Si-Yu Chen; Xiang-Quan Kong; Ke-Fan Zhang; Shuai Luo; Feng Wang; Jun-Jie Zhang
Journal:  J Inflamm Res       Date:  2022-09-16

8.  Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation.

Authors:  Ilona Cuijpers; Anna-Pia Papageorgiou; Paolo Carai; Melissa Herwig; Andreas Mügge; Thomas Klein; Nazha Hamdani; Elizabeth A V Jones; Stephane Heymans
Journal:  J Cell Mol Med       Date:  2020-12-09       Impact factor: 5.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.